肾移植受者免疫抑制方案的优化

董震; 王洪阳

doi:10.3969/j.issn.1674-7445.2024087

肾移植受者免疫抑制方案的优化

doi: 10.3969/j.issn.1674-7445.2024087

董震^,,
王洪阳

266000　青岛，青岛大学附属医院肾脏移植科

基金项目: 山东省自然科学基金青年项目（ZR2020QH237）；青岛大学附属医院青年科学基金（QDFYQN2023120）

详细信息

通讯作者:
董震（ORCID 0009-0001-2445-7748），Email: dong266000@163.com

中图分类号: R617,R392.4
计量
- 文章访问数: 97
- HTML全文浏览量: 52
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2024-03-05
- 网络出版日期: 2024-04-29
- 刊出日期: 2024-07-15

Optimization of immunosuppressive regimen for kidney transplant recipients

Dong Zhen^,,
Wang Hongyang

Department of Kidney Transplantation, the Affiliated Hospital of Qingdao University, Qingdao 266000, China

More Information

Corresponding author: Dong Zhen, Email: dong266000@163.com

摘要

摘要: 随着手术技术的成熟与发展，以及围手术期管理水平的提高，肾移植手术成功率显著提高。但由于供受者在遗传性与抗原性上存在的明显差异，会导致肾移植术后发生排斥反应，影响移植物的存活。免疫抑制是治疗排斥反应的重要手段，对减少排斥反应发生，提高移植物存活率具有重要意义。但免疫抑制药在减少排斥反应的同时会引起感染、心血管疾病、肿瘤等并发症，严重影响患者的生活质量，甚至可能导致患者死亡。合理地选择免疫抑制药，不断优化受者免疫抑制方案，对改善受者和移植肾的存活具有重要意义。因此，本文就器官移植发展史、免疫诱导治疗、免疫维持治疗进行评述，探讨肾移植受者免疫抑制方案优化取得的进展，以期为改善肾移植预后提供参考。
- 肾移植 /
- 免疫抑制药 /
- 免疫诱导 /
- 免疫维持 /
- 感染 /
- 糖皮质激素 /
- 钙调磷酸酶抑制剂 /
- 抗增殖类药物
Abstract: With the maturity and development of surgical techniques, as well as the improvement of perioperative management level, the success rate of kidney transplantation has been significantly improved. However, due to evident differences in heredity and antigenicity between donors and recipients, rejection will occur after kidney transplantation, which will affect the survival of renal grafts. Immunosuppression is an important treatment for rejection, which is of significance to reduce the risk of rejection and enhance graft survival rate. Nevertheless, immunosuppressants may cause multiple complications while lowering the incidence of rejection, such as infection, cardiovascular diseases and tumors, etc., which seriously affect the quality of life of patients and may even lead to their death. Reasonable selection of immunosuppressants and continuous optimization of immunosuppressive regimen for recipients play a critical role in improving the survival of recipients and renal grafts. In this article, the development history of organ transplantation, immune induction therapy and immune maintenance therapy was reviewed, and the progress in the optimization of immunosuppressive regimens for kidney transplant recipients was discussed, aiming to provide reference for improving clinical prognosis of kidney transplant recipients.
- Kidney transplantation /
- Immunosuppressant /
- Immune induction /
- Immune maintenance /
- Infection /
- Glucocorticoid /
- Calcineurin inhibitor /
- Antiproliferative drug

HTML全文

FIG. 3251. FIG. 3251.

FIG. 3251.. FIG. 3251.

下载: 全尺寸图片幻灯片

参考文献(38)

[1]	VIKLICKY O, NOVOTNY M, HRUBA P. Future developments in kidney transplantation[J]. Curr Opin Organ Transplant, 2020, 25(1): 92-98. DOI: 10.1097/MOT.0000000000000722.
[2]	LEMOINE CP, POZO ME, SUPERINA RA. Overview of pediatric kidney transplantation[J]. Semin Pediatr Surg, 2022, 31(3): 151194. DOI: 10.1016/j.sempedsurg.2022.151194.
[3]	BERTACCHI M, PARVEX P, VILLARD J. Antibody-mediated rejection after kidney transplantation in children; therapy challenges and future potential treatments[J]. Clin Transplant, 2022, 36(4): e14608. DOI: 10.1111/ctr.14608.
[4]	崔瑜, 张雷, 吴建永. 肾移植抗体介导排斥反应的预防及诊疗要点[J]. 中华医学杂志, 2022, 102(26): 2041-2044. DOI: 10.3760/cma.j.cn112137-20220520-01117. CUI Y, ZHANG L, WU JY. Prevention, diagnosis and treatment of antibody mediated rejection in kidney transplantation[J]. Natl Med J China, 2022, 102(26): 2041-2044. DOI: 10.3760/cma.j.cn112137-20220520-01117.
[5]	KAMAL J, DOYLE A. Immunosuppression and kidney transplantation[J]. Handb Exp Pharmacol, 2022, 272: 165-179. DOI: 10.1007/164_2021_546.
[6]	AIYEGBUSI O, MCGREGOR E, MCMANUS SK, et al. Immunosuppression therapy in kidney transplantation[J]. Urol Clin North Am, 2022, 49(2): 345-360. DOI: 10.1016/j.ucl.2021.12.010.
[7]	ZAND MS. Immunosuppression and immune monitoring after renal transplantation[J]. Semin Dial, 2005, 18(6): 511-519. DOI: 10.1111/j.1525-139X.2005.00098.x.
[8]	中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肾移植受者免疫抑制治疗指南(2016版)[J]. 器官移植, 2016, 7(5): 327-331. DOI: 10.3969/j.issn.1674-7445.2016.05.001. Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Guideline on immunosuppressive therapy of recipients with renal transplantation in China (2016 edition)[J]. Organ Transplant, 2016, 7(5): 327-331. DOI: 10.3969/j.issn.1674-7445.2016.05.001.
[9]	JARMI T, ABDELMONEIM Y, LI Z, et al. Basiliximab is associated with a lower incidence of de novo donor-specific HLA antibodies in kidney transplant recipients: a single-center experience[J]. Transpl Immunol, 2023, 77: 101778. DOI: 10.1016/j.trim.2022.101778.
[10]	YILMAZ M, SEZER TÖ, KIR O, et al. Use of ATG-Fresenius as an induction agent in deceased-donor kidney transplantation[J]. Transplant Proc, 2017, 49(3): 486-489. DOI: 10.1016/j.transproceed.2017.02.006.
[11]	Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients[J]. Am J Transplant, 2009, 9 (Suppl 3): S1-S155. DOI: 10.1111/j.1600-6143.2009.02834.x.
[12]	何跃, 郑瑾, 李杨, 等. 巴利昔单抗和抗胸腺细胞球蛋白在肾移植免疫诱导中有效性和安全性的Meta分析[J]. 器官移植, 2022, 13(4): 495-502. DOI: 10.3969/j.issn.1674-7445.2022.04.013. HE Y, ZHENG J, LI Y, et al. Efficacy and safety of basiliximab and antithymocyte globulin in immune induction in kidney transplantation: a meta-analysis[J]. Organ Transplant, 2022, 13(4): 495-502. DOI: 10.3969/j.issn.1674-7445.2022.04.013.
[13]	SABAH TK, KHALID U, ILHAM MA, et al. Induction with ATG in DCD kidney transplantation; efficacy and relation of dose and cell markers on delayed graft function and renal function[J]. Transpl Immunol, 2021, 66: 101388. DOI: 10.1016/j.trim.2021.101388.
[14]	KIM HD, BAE H, YUN S, et al. Impact of induction immunosuppressants on T lymphocyte subsets after kidney transplantation: a prospective observational study with focus on anti-thymocyte globulin and basiliximab induction therapies[J]. Int J Mol Sci, 2023, 24(18): 14288. DOI: 10.3390/ijms241814288.
[15]	LAM NN, JEONG R, QUINN RR, et al. Clinical correlates and outcomes of dual basiliximab and antithymocyte globulin induction in kidney transplant recipients: a national study[J]. Transplant Direct, 2021, 7(8): e736. DOI: 10.1097/TXD.0000000000001190.
[16]	王兰君, 靳隽, 李梦琪, 等. 他克莫司血药浓度对肾病综合征患者肝肾功能和血糖的影响[J]. 新乡医学院学报, 2022, 39(3): 243-247. DOI: 10.7683/xxyxyxb.2022.03.009. WANG LJ, JIN J, LI MQ, et al. Effect of blood concentration of tacrolimus on liver function, kidney function and blood glucose of patients with nephrotic syndrome[J]. J Xinxiang Med Univ, 2022, 39(3): 243-247. DOI: 10.7683/xxyxyxb.2022.03.009.
[17]	YOUSIF E, ABDELWAHAB A. Post-transplant diabetes mellitus in kidney transplant recipients in sudan: a comparison between tacrolimus and cyclosporine-based immunosuppression[J]. Cureus, 2022, 14(2): e22285. DOI: 10.7759/cureus.22285.
[18]	SUN X, WANG H, CHI J, et al. Endoplasmic reticulum stress in the adipose tissue and monocyte chemoattractant protein-1 are involved in tacrolimus-induced diabetes mellitus[J]. Pharmacol Res Perspect, 2023, 11(3): e01081. DOI: 10.1002/prp2.1081.
[19]	WANG Q, WU J, WANG X, et al. Risk factors of new-onset diabetes after renal transplantation and prognostic analysis[J]. Altern Ther Health Med, 2023, 29(2): 230-235.
[20]	杨帆, 倪兆慧. 肾移植术后BK病毒相关肾病的诊治进展[J/OL]. 中华肾病研究电子杂志, 2022, 11(2): 90-93. DOI: 10.3877/cma.j.issn.2095-3216.2022.02.007. YANG F, NI ZH. Progress in diagnosis and treatment of BKV-associated nephropathy in patients after kidney transplantation[J/OL] Chin J Kidney Dis Invest (Electr Edit), 2022, 11(2): 90-93. DOI: 10.3877/cma.j.issn.2095-3216.2022.02.007.
[21]	BORRIELLO M, INGROSSO D, PERNA AF, et al. BK virus infection and BK-virus-associated nephropathy in renal transplant recipients[J]. Genes (Basel), 2022, 13(7): 1290. DOI: 10.3390/genes13071290.
[22]	FUNAHASHI Y. BK virus-associated nephropathy after renal transplantation[J]. Pathogens, 2021, 10(2): 150. DOI: 10.3390/pathogens10020150.
[23]	CHEN XT, LI J, DENG RH, et al. The therapeutic effect of switching from tacrolimus to low-dose cyclosporine A in renal transplant recipients with BK virus nephropathy[J]. Biosci Rep, 2019, 39(2): BSR20182058. DOI: 10.1042/BSR20182058.
[24]	BORATYŃSKA M, BANASIK M, PATRZAŁEK D,et al. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection[J]. Ann Transplant, 2006, 11(2): 51-56.
[25]	王梓宇, 王洪阳, 王清海, 等. 转换使用他克莫司缓释胶囊对肾移植受者治疗有效性及安全性的影响[J]. 精准医学杂志, 2022, 37(5): 400-403. DOI: 10.13362/j.jpmed.202205006. WANG ZY, WANG HY, WANG QH, et al. Effect of conversion to tacrolimus sustained-release capsules on treatment efficacy and safety in kidney transplant recipients[J]. J Precis Med, 2022, 37(5): 400-403. DOI: 10.13362/j.jpmed.202205006.
[26]	中华医学会器官移植学分会, 中国医师协会器官移植医师分会, 上海医药行业协会, 等. 中国肝、肾移植受者霉酚酸类药物应用专家共识(2023版)[J]. 上海医药, 2023, 44(19): 3-19,47. DOI: 10.3969/j.issn.1006-1533.2023.19.002. Branch of Organ Transplantation of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Industry Association, et al. Expert consensus on the use of mycophenolic acid in Chinese liver and kidney transplant recipients (2023 edition)[J]. Shanghai Med Pharm J, 2023, 44(19): 3-19,47. DOI: 10.3969/j.issn.1006-1533.2023.19.002.
[27]	SAVVIDAKI E, PAPACHRISTOU E, KAZAKOPOULOS P, et al. Gastrointestinal disorders after renal transplantation[J]. Transplant Proc, 2014, 46(9): 3183-3186. DOI: 10.1016/j.transproceed.2014.09.155.
[28]	GABARDI S, TRAN JL, CLARKSON MR. Enteric-coated mycophenolate sodium[J]. Ann Pharmacother, 2003, 37(11): 1685-1693. DOI: 10.1345/aph.1D063.
[29]	GHADDAR M, BARRATT J, BARBOUR SJ. An update on corticosteroid treatment for IgA nephropathy[J]. Curr Opin Nephrol Hypertens, 2023, 32(3): 263-270. DOI: 10.1097/MNH.0000000000000881.
[30]	ROVIN BH. IgA nephropathy and glucocorticoids-a limbo dance?[J]. Kidney Int, 2023, 103(4): 673. DOI: 10.1016/j.kint.2023.01.017.
[31]	CAMPBELL KN. Oral glucocorticoids for IgA nephropathy[J]. JAMA, 2022, 327(19): 1872-1874. DOI: 10.1001/jama.2022.4638.
[32]	QIN Y, ZHANG F, SHEN B, et al. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation[J]. Int J Clin Pract Suppl, 2014(181): 17-22. DOI: 10.1111/ijcp.12402.
[33]	CHEN J, LIU H, YIN W, et al. The efficacy and safety of mizoribine versus mycophenolate mofetil for the treatment of renal transplantation: a systematic review and meta-analysis[J]. Comput Intell Neurosci, 2022, 2022: 5717068. DOI: 10.1155/2022/5717068.
[34]	LI P, CHENG D, WEN J, et al. Conversion from mycophenolate mofetil to mizoribine in the early stages of BK polyomavirus infection could improve kidney allograft prognosis: a single-center study from China[J]. BMC Nephrol, 2021, 22(1): 328. DOI: 10.1186/s12882-021-02527-3.
[35]	SANTEUSANIO AD, LUKENS BE, EUN J. Antiviral treatment of BK virus viremia after kidney transplantation[J]. Am J Health Syst Pharm, 2017, 74(24): 2037-2045. DOI: 10.2146/ajhp160585.
[36]	CATANEO-DÁVILA A, ZÚÑIGA-VARGA J, CORREA-ROTTER R, et al. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination[J]. Transplant Proc, 2009, 41(10): 4138-4146. DOI: 10.1016/j.transproceed.2009.08.065.
[37]	TAMMISETTI VS, PRASAD SR, DASYAM N, et al. Immunosuppressive therapy in solid organ transplantation: primer for radiologists and potential complications[J]. Radiol Clin North Am, 2023, 61(5): 913-932. DOI: 10.1016/j.rcl.2023.04.010.
[38]	KAUFFMAN HM, CHERIKH WS, MCBRIDE MA, et al. Post-transplant de novo malignancies in renal transplant recipients: the past and present[J]. Transpl Int, 2006, 19(8): 607-620. DOI: 10.1111/j.1432-2277.2006.00330.x.